In a pre-close trading update, the AIM company revealed that revenues rose 32% to £5.4mln in the 12 months ended September 30 (2017: £4.1mln). Total income rose 25% to £6.0mln (2017: £4.8mln).
During the year, IXICO announced several contracts worth over £15mln, including a recent £9.1mln deal to provide insight from magnetic resonance imaging (MRI) data to assist in phase III clinical trial for a drug to treat Huntington's disease.
“These new contracts and existing projects provide a foundation for future revenue growth,” read Monday’s statement.
Net cash at the end of September totalled £7.9mln (2017: £2.4mln), reflecting an oversubscribed £5.5mln placing back in May as well as an R&D tax credit receipt of £0.4mln.
The full set of results are scheduled to published on December 4.